약제 용출형 스텐트 시장 보고서 : 코팅, 약제, 스텐트 플랫폼, 세대, 용도, 최종사용자 및 지역별(2026-2034년)

The global drug-eluting stents market size reached USD 9.2 Billion in 2025. Looking forward, the market is expected to reach USD 14.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.03% during 2026-2034. The increasing prevalence of cardiovascular diseases is propelling the market.

DRUG-ELUTING STENTS MARKET ANALYSIS:

• Major Market Drivers: The increasing prevalence of irregular heart rhythms, heart failure, and heart attack disease is stimulating the market.
• Key Market Trends: The widespread use of stents with polymer-free coatings is acting as a significant growth-inducing factor.
• Competitive Landscape: Some of the major market companies include Abbott, B. Braun SE, Biosensors International Group, Ltd., Biotronik, Boston Scientific Corporation, Cook Medical, Lepu Medical Technology (Beijing) Co., Ltd, Medinol, Medtronic plc, MicroPort Scientific Corporation, Sino Medical Sciences Technology Inc and Terumo Corporation, among many others.
• Geographical Trends: North America dominates the market owing to a robust healthcare system, rising incidence of coronary artery disease, and extensive use of innovative medical technologies.
• Challenges and Opportunities: The risk of late stent thrombosis is hampering the market. However, developing innovative stent technologies with greater biocompatibility and polymer-free coatings to increase patient safety is expected to fuel the market in the coming years.

DRUG-ELUTING STENTS MARKET TRENDS:

Implementation of Next-Generation Drugs

The next generation of drug-eluting stents uses advanced medications, such as biolimus and zotarolimus, which have higher efficacy in preventing restenosis while reducing adverse effects, making these stents more useful for a wider variety of patients. For example, in May 2024, Abbott announced the launch of XIENCE Sierra Everolimus (drug) eluting coronary stent system in India. It is a CE-marked and one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. This is leading to the drug-eluting stents market growth.

Expanded Use in Peripheral Artery Disease

Drug-eluting stents are being increasingly utilized to treat peripheral arterial disease (PAD), moving beyond coronary applications. This trend reflects stents' growing use in treating blockages in arteries beyond the heart. In April 2024, Cook Medical received a contract to supply implantable devices to hospitals run by the U.S. Department of Defense (DoD). The company would provide its Zilver PTX drug-eluting peripheral stent, Zenith aortic endograft, and other implantable devices. This is expanding the drug-eluting stents market share.

Increasing Focus on Complex Lesions

Drug-eluting stents are in high demand for treating complicated coronary lesions such as bifurcation and multi-vessel disease. These advanced stents are designed to handle complex anatomical issues with more precision. In June 2024, Elixir Medical's DynamX Sirolimus-Eluting Coronary Bioadaptor System received Breakthrough Device Designation from the FDA. This bioadaptive implant aims to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease.

GLOBAL DRUG-ELUTING STENTS INDUSTRY SEGMENTATION:

Breakup by Coating:

• Polymer Based Coating
• Polymer Free Coating

Among these, polymer free coating holds the largest share of the drug-eluting stents market

Polymer free coating is intended to minimize inflammation and promote healing. These coatings improve medication delivery while eliminating the problems associated with polymers, resulting in better patient outcomes during cardiovascular treatments. This is elevating the drug-eluting stents market revenue.

Breakup by Drug:

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Biolimus
• Others

The drug-eluting stents market overview highlights that sirolimus reduces cell development to avoid arterial narrowing, while paclitaxel inhibits cell division, resulting in better blood flow. Zotarolimus enhances healing while causing less adverse effects, and everolimus has been shown to reduce re-narrowing over time. Biolimus, a biodegradable alternative, promotes vascular recovery, providing a variety of therapy options in the market.

Breakup by Stent Platform:

• Stainless-steel
• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Others

Cobalt-chromium currently holds the largest drug-eluting stents market demand

Cobalt-chromium stents are well-known for their long-lasting, flexible, and biocompatible design. These stents have a sturdy construction but allow for thinner struts, which improves vessel support and reduces problems during cardiovascular treatments. This is elevating the drug-eluting stents market statistics.

Breakup by Generation:

• 1st Generation
• 2nd Generation
• 3rd Generation
• 4th Generation

The 1st generation drug-eluting stents used basic drug coatings to minimize restenosis. The 2nd generation increased safety by improving biocompatibility and using thinner struts. The 3rd generation focused on biodegradable polymers to improve healing, while the 4th generation uses polymer-free coatings to promote speedier recovery and reduce inflammation. Each generation represents advances in safety, efficacy, and patient outcomes.

Breakup by Application:

• Coronary Artery Disease
• Peripheral Artery Disease

Currently, coronary artery disease holds the largest share of the drug-eluting stents market recent price

The market largely focuses on coronary artery disease by releasing medications that prevent restenosis. These stents help to maintain artery patency, improve blood flow, and reduce the need for repeat treatments in patients with blocked or narrowed arteries.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Among these, hospitals currently hold the largest share of the market

Hospitals are the primary end users in this market, as these devices are commonly utilized in cardiovascular surgeries to treat coronary artery disease. These stents are used in hospitals to improve patient outcomes, lower restenosis, and reduce the need for recurrent treatments. This represents one of the drug-eluting stents market recent opportunities.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the drug-eluting stents market outlook

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America exhibits a clear dominance in the market. This can be attributed to the enhanced healthcare infrastructure, a high prevalence of cardiovascular illnesses, and the growing adoption of cutting-edge stent technology. The region's focus on reducing coronary artery disease promotes demand for these devices.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major drug-eluting stents market companies have also been provided. Some of the key players in the market include:

• Abbott
• B. Braun SE
• Biosensors International Group, Ltd.
• Biotronik
• Boston Scientific Corporation
• Cook Medical
• Lepu Medical Technology (Beijing) Co., Ltd
• Medinol
• Medtronic plc
• MicroPort Scientific Corporation
• Sino Medical Sciences Technology Inc
• Terumo Corporation

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global drug-eluting stents market in 2025?

2. What is the expected growth rate of the global drug-eluting stents market during 2026-2034?

3. What are the key factors driving the global drug-eluting stents market?

4. What has been the impact of COVID-19 on the global drug-eluting stents market?

5. What is the breakup of the global drug-eluting stents market based on the coating?

6. What is the breakup of the global drug-eluting stents market based on the stent platform?

7. What is the breakup of the global drug-eluting stents market based on application?

8. What is the breakup of the global drug-eluting stents market based on the end user?

9. What are the key regions in the global drug-eluting stents market?

10. Who are the key players/companies in the global drug-eluting stents market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Drug-Eluting Stents Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Coating

• 6.1 Polymer Based Coating
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Polymer Free Coating
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug

• 7.1 Sirolimus
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Paclitaxel
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Zotarolimus
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Everolimus
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Biolimus
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Stent Platform

• 8.1 Stainless-steel
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cobalt-Chromium
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Platinum-Chromium
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Nitinol
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Generation

• 9.1 1st Generation
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 2nd Generation
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 3rd Generation
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 4th Generation
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Application

• 10.1 Coronary Artery Disease
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Peripheral Artery Disease
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast

11 Market Breakup by End User

• 11.1 Hospitals
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Ambulatory Surgical Centers
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Others
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast

12 Market Breakup by Region

• 12.1 North America
  • 12.1.1 United States
    • 12.1.1.1 Market Trends
    • 12.1.1.2 Market Forecast
  • 12.1.2 Canada
    • 12.1.2.1 Market Trends
    • 12.1.2.2 Market Forecast
• 12.2 Asia-Pacific
  • 12.2.1 China
    • 12.2.1.1 Market Trends
    • 12.2.1.2 Market Forecast
  • 12.2.2 Japan
    • 12.2.2.1 Market Trends
    • 12.2.2.2 Market Forecast
  • 12.2.3 India
    • 12.2.3.1 Market Trends
    • 12.2.3.2 Market Forecast
  • 12.2.4 South Korea
    • 12.2.4.1 Market Trends
    • 12.2.4.2 Market Forecast
  • 12.2.5 Australia
    • 12.2.5.1 Market Trends
    • 12.2.5.2 Market Forecast
  • 12.2.6 Indonesia
    • 12.2.6.1 Market Trends
    • 12.2.6.2 Market Forecast
  • 12.2.7 Others
    • 12.2.7.1 Market Trends
    • 12.2.7.2 Market Forecast
• 12.3 Europe
  • 12.3.1 Germany
    • 12.3.1.1 Market Trends
    • 12.3.1.2 Market Forecast
  • 12.3.2 France
    • 12.3.2.1 Market Trends
    • 12.3.2.2 Market Forecast
  • 12.3.3 United Kingdom
    • 12.3.3.1 Market Trends
    • 12.3.3.2 Market Forecast
  • 12.3.4 Italy
    • 12.3.4.1 Market Trends
    • 12.3.4.2 Market Forecast
  • 12.3.5 Spain
    • 12.3.5.1 Market Trends
    • 12.3.5.2 Market Forecast
  • 12.3.6 Russia
    • 12.3.6.1 Market Trends
    • 12.3.6.2 Market Forecast
  • 12.3.7 Others
    • 12.3.7.1 Market Trends
    • 12.3.7.2 Market Forecast
• 12.4 Latin America
  • 12.4.1 Brazil
    • 12.4.1.1 Market Trends
    • 12.4.1.2 Market Forecast
  • 12.4.2 Mexico
    • 12.4.2.1 Market Trends
    • 12.4.2.2 Market Forecast
  • 12.4.3 Others
    • 12.4.3.1 Market Trends
    • 12.4.3.2 Market Forecast
• 12.5 Middle East and Africa
  • 12.5.1 Market Trends
  • 12.5.2 Market Breakup by Country
  • 12.5.3 Market Forecast

13 SWOT Analysis

• 13.1 Overview
• 13.2 Strengths
• 13.3 Weaknesses
• 13.4 Opportunities
• 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

• 17.1 Market Structure
• 17.2 Key Players
• 17.3 Profiles of Key Players
  • 17.3.1 Abbott
    • 17.3.1.1 Company Overview
    • 17.3.1.2 Product Portfolio
    • 17.3.1.3 Financials
    • 17.3.1.4 SWOT Analysis
  • 17.3.2 B. Braun SE
    • 17.3.2.1 Company Overview
    • 17.3.2.2 Product Portfolio
    • 17.3.2.3 SWOT Analysis
  • 17.3.3 Biosensors International Group, Ltd.
    • 17.3.3.1 Company Overview
    • 17.3.3.2 Product Portfolio
  • 17.3.4 Biotronik
    • 17.3.4.1 Company Overview
    • 17.3.4.2 Product Portfolio
    • 17.3.4.3 SWOT Analysis
  • 17.3.5 Boston Scientific Corporation
    • 17.3.5.1 Company Overview
    • 17.3.5.2 Product Portfolio
    • 17.3.5.3 Financials
    • 17.3.5.4 SWOT Analysis
  • 17.3.6 Cook Medical
    • 17.3.6.1 Company Overview
    • 17.3.6.2 Product Portfolio
    • 17.3.6.3 SWOT Analysis
  • 17.3.7 Lepu Medical Technology (Beijing) Co., Ltd
    • 17.3.7.1 Company Overview
    • 17.3.7.2 Product Portfolio
    • 17.3.7.3 Financials
  • 17.3.8 Medinol
    • 17.3.8.1 Company Overview
    • 17.3.8.2 Product Portfolio
    • 17.3.8.3 Financials
    • 17.3.8.4 SWOT Analysis
  • 17.3.9 Medtronic plc
    • 17.3.9.1 Company Overview
    • 17.3.9.2 Product Portfolio
    • 17.3.9.3 Financials
    • 17.3.9.4 SWOT Analysis
  • 17.3.10 MicroPort Scientific Corporation
    • 17.3.10.1 Company Overview
    • 17.3.10.2 Product Portfolio
  • 17.3.11 Sino Medical Sciences Technology Inc
    • 17.3.11.1 Company Overview
    • 17.3.11.2 Product Portfolio
  • 17.3.12 Terumo Corporation
    • 17.3.12.1 Company Overview
    • 17.3.12.2 Product Portfolio
    • 17.3.12.3 Financials
    • 17.3.12.4 SWOT Analysis